Unconfigured Ad

Collapse
X
 
  • Time
  • Show
Clear All
new posts
  • Wiseone
    Junior Member
    • Apr 2010
    • 7

    #1

    Question on mapping reads

    Hey all,
    I am currently working with SE reads (75bp) from 4 independent samples. Sequencing generated approximately 25 million reads per sample (100 million total). My goal is to perform RNA seq to look at gene expression. I am using CLC workbench.
    Before I performed the de novo assembly I filtered reads less than 15 bp long and with greater than 2 uncalled bases (N). After performing the de novo assembly on the 100 million reads I get approximately 193000 contigs, with a min size of 100bp.
    I have begun performing the RNA seq and the first thing I noticed was that only approximately 30% of the reads from the individual samples are mapping back to the contigs. Am I right in saying that this number is very low? The unmapped reads are a mix of long and short reads, they appear to be high quality, and when I randomly blast them with blastn I get strong matches to sequences from related species. I tried relaxing the mapping parameters some but it only increased the number of reads mapping by 5%.
    I am very much beginner when it comes to this technology and what I have learned so far comes from trial and error on my part, as well as a question or two that I have posted on this forum. It seems to me that if you are mapping reads to contigs generated from those reads then the mapping efficiency should be much higher than 30-35%. I will continue to play with the mapping and the de novo assembly to try and improve the mapping but I was hoping someone on here could comment and maybe provide some insight into this.
    Thanks!

Latest Articles

Collapse

  • SEQadmin2
    Proteomic Platforms: How to Choose the Right Analytical Strategy to Improve Detection and Clinical Applications
    by SEQadmin2


    Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.

    The systematic characterization of the human proteome has
    ...
    07-20-2026, 11:48 AM
  • SEQadmin2
    Advanced Sequencing Platforms Tackle Neuroscience’s Toughest Genomics Problems
    by SEQadmin2



    Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
    ...
    07-09-2026, 11:10 AM
  • SEQadmin2
    Cancer Drug Resistance: The Lingering Barrier to Rising Survival
    by SEQadmin2



    Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.

    There is no single reason why many patients don’t respond to treatment as expected. Cancer is...
    07-08-2026, 05:17 AM

ad_right_rmr

Collapse

News

Collapse

Topics Statistics Last Post
Started by SEQadmin2, 07-24-2026, 12:17 PM
0 responses
10 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 07-23-2026, 11:41 AM
0 responses
11 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 07-20-2026, 11:10 AM
0 responses
23 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 07-13-2026, 10:26 AM
0 responses
37 views
0 reactions
Last Post SEQadmin2  
Working...